Literature DB >> 31025112

Cisplatin-based chemoradiotherapy trumps cetuximab-based bioradiotherapy in p16/HPV-positive oropharyngeal cancers.

Monali Swain1, Tejpal Gupta2, Sadhana Kannan3, JaiPrakash Agarwal1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31025112     DOI： 10.1007/s00405-019-05441-5

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN： 0937-4477            Impact factor:   2.503


× No keyword cloud information.
  4 in total

1.  Concurrent Chemoradiotherapy With Cisplatin Versus Cetuximab for Squamous Cell Carcinoma of the Head and Neck.

Authors:  Nadeem Riaz; Eric Sherman; Lawrence Koutcher; Lauren Shapiro; Nora Katabi; Zhigang Zhang; Weiji Shi; Mathew Fury; Richard Wong; Suzanne Wolden; Shyam Rao; Nancy Lee
Journal:  Am J Clin Oncol       Date:  2016-02       Impact factor: 2.339

2.  Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE.

Authors:  Petar Suton; Marko Skelin; Zoran Rakusic; Stjepan Dokuzovic; Ivica Luksic
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-03-18       Impact factor: 2.503

3.  Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.

Authors:  Maura L Gillison; Andy M Trotti; Jonathan Harris; Avraham Eisbruch; Paul M Harari; David J Adelstein; Richard C K Jordan; Weiqiang Zhao; Erich M Sturgis; Barbara Burtness; John A Ridge; Jolie Ringash; James Galvin; Min Yao; Shlomo A Koyfman; Dukagjin M Blakaj; Mohammed A Razaq; A Dimitrios Colevas; Jonathan J Beitler; Christopher U Jones; Neal E Dunlap; Samantha A Seaward; Sharon Spencer; Thomas J Galloway; Jack Phan; James J Dignam; Quynh Thu Le
Journal:  Lancet       Date:  2018-11-15       Impact factor: 79.321

4.  Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.

Authors:  Hisham Mehanna; Max Robinson; Andrew Hartley; Anthony Kong; Bernadette Foran; Tessa Fulton-Lieuw; Matthew Dalby; Pankaj Mistry; Mehmet Sen; Lorcan O'Toole; Hoda Al Booz; Karen Dyker; Rafael Moleron; Stephen Whitaker; Sinead Brennan; Audrey Cook; Matthew Griffin; Eleanor Aynsley; Martin Rolles; Emma De Winton; Andrew Chan; Devraj Srinivasan; Ioanna Nixon; Joanne Grumett; C René Leemans; Jan Buter; Julia Henderson; Kevin Harrington; Christopher McConkey; Alastair Gray; Janet Dunn
Journal:  Lancet       Date:  2018-11-15       Impact factor: 79.321
  4 in total
  1 in total

1.  In reply to Swain et al.: Re-evaluation of updated meta-analysis including trials RTOG 1016 and De-ESCALaTE.

Authors:  Petar Suton; Marko Skelin; Zoran Rakusic; Stjepan Dokuzovic; Ivica Luksic
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-05-27       Impact factor: 2.503
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.